Botulinum Toxin Injection for the Management of BPH (MIST2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00451191 |
Recruitment Status
:
Completed
First Posted
: March 23, 2007
Results First Posted
: June 24, 2013
Last Update Posted
: June 24, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Benign Prostatic Hyperplasia | Drug: botulinum toxin type A (BoNT/A) | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 134 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Intraprostatic Injection of Botulinum Toxin for the Management of Benign Prostatic Hyperplasia: A Randomized Phase II Trial |
Study Start Date : | October 2006 |
Actual Primary Completion Date : | June 2009 |
Actual Study Completion Date : | December 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
100 units botulinum toxin type A (BoNT/A)
|
Drug: botulinum toxin type A (BoNT/A)
100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
Other Name: marketed in the US as BOTOX by Allergan
|
Active Comparator: 2
300 units botulinum toxin type A (BoNT/A)
|
Drug: botulinum toxin type A (BoNT/A)
100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
Other Name: marketed in the US as BOTOX by Allergan
|
- Improvement in the AUA Symptom Score Index by 30% From Baseline Within the First 12 Weeks After Injection. [ Time Frame: 12 weeks ]The primary outcome was treatment success at 3 months post-treatment, defined as (1) improvement in the AUASI by at least 30% and/or (2) Qmax improvement of more than 30%, each determined from baseline to 3 months after injection. In addition, two safety criteria also had to be met; a dose failed if (1) any reported event was determined to be related to the onabotulinum toxin A injection and was considered life threatening, disabling, or fatal or (2) >=40% of the participants reported a moderate or severe side effect related to the botulinum toxin injection.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male at least 50 years of age.
- Voided volume => 125 ml.
- Maximum urinary flow < 15 ml/sec.
- AUA symptom severity score => 8.
- Patient signed informed consent prior to the performance of any study procedures.
- Patient able to complete the study protocol in the opinion of the investigator.
Exclusion Criteria:
- Any prior surgical intervention for BPH.
- Current diagnosis of acute or chronic prostatitis (which may cause LUTS that mimic BPH).
- Overactive bladder without bladder outlet obstruction.
- Enrolled in another treatment trial for any disease within the past 30 days.
- Men interested in future fertility.
- Previous exposure to botulinum toxin.
- On alpha-blocker within the past 48 hours.
- On any 5-alpha-reductase inhibitor within the past month.
- Post void residual > 350 ml.
- On phenylephrine, pseudoephedrine, imipramine, an anticholinergic, or cholinergic medication within the past 2 weeks.
- On estrogen, androgen, any drug producing androgen suppression, or anabolic steroids within the past 4 months.
- Clinically significant renal or hepatic impairment as determined by abnormal creatinine or AST levels (based on local institutional values).
- Serum prostate specific antigen level > 8 ng/ml (Hybritech). For those with a PSA between 4-8 ng/ml, the PSA elevation must be considered to be from a benign cause in the opinion of the PI. This decision can be based on PSA velocity, previous TRUS biopsy, percent free PSA, or other clinical estimations in keeping with sound urologic care.
- Active urinary tract disease or biopsy of the prostate within the past 6 weeks.
- Daily use of a pad or device for incontinence required.
- Episode of unstable angina pectoris, myocardial infarction, transient ischemic attack, or cerebrovascular accident (stroke) within the past 6 months.
- On aminoglycosides or any drug that interfere with neuromuscular transmission.
- Eaton-Lambert syndrome, hemophilia, hereditary clotting factors deficiency, or bleeding diathesis.
- Penile prosthesis or artificial urinary sphincter.
- History or current evidence of carcinoma of the prostate or bladder, pelvic radiation or surgery, urethral stricture, or bladder neck obstruction.
- Known primary neurologic conditions such as multiple sclerosis, myasthenia gravis or Parkinson's disease, or other neurological diseases known to affect bladder function.
- Documented bacterial or acute prostatitis within the past year.
- Two documented urinary tract infections of any type in the past year (UTI defined as > 100,000 colonies per ml urine from midstream clean catch or catheterized specimen).
- History of bladder calculi.
- Patients must be off aspirin, NSAIDS, and Coumadin for 7 or more days prior to botulinum toxin injection.
- Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years).
- Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, hypersensitivity to botulinum toxin or anesthetics used in the study, syncope, uncontrolled diabetes.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00451191
United States, Colorado | |
University of Colorado Health Sciences Center | |
Denver, Colorado, United States, 80010 | |
United States, Illinois | |
Northwestern University | |
Chicago, Illinois, United States, 60611 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, New York | |
Cornell University | |
New York, New York, United States, 10021 | |
United States, Texas | |
University of Texas Southwestern Medical Center | |
Dallas, Texas, United States, 75390 | |
Baylor College of Medicine | |
Houston, Texas, United States, 77030 | |
United States, Wisconsin | |
Medical College of Wisconsin | |
Milwaukee, Wisconsin, United States, 53226 |
Study Chair: | Reginald Bruskewitz, MD | University of Wisconsin, Madison |
Publications of Results:
Responsible Party: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00451191 History of Changes |
Obsolete Identifiers: | NCT00395525 |
Other Study ID Numbers: |
MIST2 5U01DK060817 ( U.S. NIH Grant/Contract ) |
First Posted: | March 23, 2007 Key Record Dates |
Results First Posted: | June 24, 2013 |
Last Update Posted: | June 24, 2013 |
Last Verified: | June 2013 |
Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
benign prostatic hyperplasia BPH botulinum toxin BoNT/A |
Additional relevant MeSH terms:
Hyperplasia Prostatic Hyperplasia Pathologic Processes Prostatic Diseases Genital Diseases, Male Botulinum Toxins Botulinum Toxins, Type A onabotulinumtoxinA abobotulinumtoxinA |
Acetylcholine Release Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents |